<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665260</url>
  </required_header>
  <id_info>
    <org_study_id>12-01-004</org_study_id>
    <nct_id>NCT02665260</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum</brief_title>
  <official_title>Randomized Pilot Study Investigating the Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if cantharidin is a safe and effective treatment
      for molluscum contagiosum in kids
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, placebo-controlled trial. Participants were recruited from the
      Pediatric Dermatology clinic at Montefiore Medical Center. One hundred eligible participants
      were randomly assigned to receive cantharidin 0.7% topical, cantharidin 0.7% topical with
      occlusion, placebo, or placebo with occlusion. Treatments were applied at weeks 0 and 3
      (blinded phase). At week 6, all participants were treated with open-label, topical
      cantharidin 0.7% without occlusion every 3 weeks until all lesions resolved (open-label
      phase).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who achieve complete clearance at 6 weeks and 33 weeks</measure>
    <time_frame>33 weeks</time_frame>
    <description>Assess percentage of subjects who achieve a lesion count of zero at 6 weeks (end of blinded phase) and 33 weeks (end of open-label phase)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>33 weeks</time_frame>
    <description>Assessed by patient-reported outcomes questionnaire at each visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Molluscum Contagiosum</condition>
  <arm_group>
    <arm_group_label>Cantharidin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cantharidin 0.7% topical</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo topical</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cantharidin</intervention_name>
    <description>cantharidin 0.7% topical liquid</description>
    <arm_group_label>Cantharidin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>2,6-Dimethyl-4,10-dioxatricyclo-decane-3,5-dione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo topical liquid</description>
    <arm_group_label>Cantharidin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>flexible collodion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2-17years

          -  Healthy

          -  &lt;50 molluscum contagiosum lesions

        Exclusion Criteria:

          -  Immunosuppressed

          -  Oral corticosteroids

          -  Sexually active/pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 22, 2016</lastchanged_date>
  <firstreceived_date>December 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Molluscum Contagiosum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cantharidin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
